KRAS and non-small cell lung carcinoma: In the phase II BASALT-1 trial, buparlisib, a pan-PI3K inhibitor, was tested in a cohort of 63 patients with pretreated NSCLC harboring a PI3K pathway activation, including 3 patients with concomitant KRAS alterations; the study was closed due to futility, with a 12-week PFS of 23.3% and 20% in squamous and non-squamous histology (93).